Looks like Penn Cannabis growing/selling taking off
Looks like Penn Cannabis growing/selling taking off already!
$UNVC
http://www.cpbj.com/apps/pbcs.dll/article?AID...=mobileart
What is the sales revenue for medical marijuana in Penn so far?
Pennsylvania's medical marijuana market could someday reach hundreds of millions of dollars in annual sales.
It is not there yet.
State-specific revenue is hard to come by in the medical cannabis industry. And most companies in the field are privately held, so they do not report numbers publicly.
But there is a hint in Pennsylvania's tax-collection records.
By the end of July, the state had collected $60,086.16 in medical marijuana taxes, according to revenue and receipts reports from the Pennsylvania Department of Revenue. The money comes from a 5 percent levy assessed on gross receipts from sales by growers and processors to dispensers. There is no additional tax charged at the point of sale to patients.
Growers and processors pay the tax on a quarterly basis, according to the revenue department, with deadlines coming at the end of January, April, July and October.
The state's first dispensaries opened in mid February. Assuming everyone paid the tax on time and in full, Pennsylvania's 12 growers and processors sold slightly more than $1.2 million worth of medical marijuana by the end of April 2018.
On an annualized basis with full quarters of operation, that would mean at least $5 million in sales, though the quarterly figures are likely to rise as more patients choose treatment via medical marijuana. The state also is adding more grower/processors, bringing the total to 25.
One company with operations in Pennsylvania, Chicago-based Green Thumb Industries, recently went public in Canada and said its 2017 revenue exceeded $20 million in 2017. Its dispensaries operate under the RISE brand, and it also is a manufacturer, with operations in Florida, Maryland, Massachusetts, Nevada and Ohio, in addition to the Keystone state.
Trade publication Marijuana Business Daily estimates that the Pennsylvania market could exceed $100 million in annual sales in a few years based on a patient base of 100,000 to 200,000 people.
According to the Pennsylvania Department of Health, more than 60,000 patients have registered for the state's medical marijuana program and nearly 38,000 had obtained medical marijuana identification cards allowing them to purchase cannabis for treatment
Another analysis - by a pair of research firms called New Frontier Data and Arcview Market Research - puts the potential size of Pennsylvania’s market at $700 million in annual sales by 2020.
That could mean up to $35 million in annual tax revenue, depending on how much of the total comes from growers/processors as opposed to retail dispensaries.
Either way, it is short of the revenue some officials say could be collected from the legalization of recreational marijuana in Pennsylvania. In July Auditor General Eugene DePasquale estimated the tax haul would be at least $581 million.
1
Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...
Continue Reading
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Merger in the Life Sciences Sector In a significant move for the life sciences industry, Waters Corporation (NYSE: WAT) has officially announced its plans to merge with BD (Becton, Dickinson and Company) (NYSE: BDX). This merger aims to create a leading entity in the fields of regulated and high-volume testing. The combination is expected to harness the strengths...
Continue Reading
Citius Oncology Reinforces Distribution for LYMPHIR Citius Oncology, Inc. (Nasdaq: CTOR), a leading company in oncology therapeutics, has taken a significant step by partnering with Cencora, a global provider of pharmaceutical solutions. The newly signed distribution services agreement is aimed at enhancing commercial infrastructure and ensuring the successful launch of...
Continue Reading
Surging Growth in Low-Code Development Platforms The demand for low-code development platforms is on the rise, with projected growth from USD 26.30 billion in 2025 up to USD 67.12 billion by 2030, at an impressive CAGR of 20.61%. This surge is primarily fueled by organizations adopting hybrid and multi-cloud strategies, making low-code tools essential for modernizing...
Continue Reading
Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has...
Continue Reading
Why May is the Optimal Time for Real Estate Transactions As the weather warms and spring settles in, the real estate market bursts with activity. Leading property experts suggest that May is the prime month to either buy or sell a home. Mish Liyanage, the CEO of Mistoria Group, emphasizes that emerging market trends provide compelling reasons for homeowners and potential...
Continue Reading